Arbutus biopharma corp (ABUS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
OPERATING ACTIVITIES
Net Income (Loss) Attributable to Parent

-144,333

-153,723

-147,318

-89,288

-62,882

-57,060

-74,742

-61,869

-83,215

-84,413

-267,177

-275,172

-386,917

-384,164

-172,330

-181,717

-66,603

-62,718

-62,025

-41,647

-32,842

-38,837

-35,267

-29,677

-29,501

-14,063

0

0

0

Items not involving cash:
Deferred income tax benefit

-

-

0

-

-

-

0

-

-

-

0

-

-

-

0

0

-

-

0

0

-

-

0

-

-

-

-

-

-

Depreciation

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

2,027

1,739

1,437

1,209

1,092

929

791

686

589

533

513

515

529

563

582

581

613

0

0

0

Gain on sale of property and equipment

-29

-20

11

37

35

26

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

6,722

6,799

7,619

7,931

6,808

6,241

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized foreign exchange losses (gains)

20

68

-137

18

-400

-1,003

-998

199

1,384

2,374

1,451

-703

-1,578

1,003

7,887

20,503

17,915

21,966

19,453

6,272

0

-

0

0

-

18

0

0

0

Warrant issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-22

169

179

347

530

903

2,869

4,725

3,341

5,337

-1,779

2,010

-10,383

-14,318

-9,206

-17,454

-3,530

0

0

0

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

-225

-200

-1,156

-6,388

-6,325

-7,298

-6,050

-245

-548

1,359

1,958

2,021

2,383

1,568

1,526

1,266

1,014

770

0

0

0

-

-

-

-

-

-

-

-

Impairment of Intangible Assets (Excluding Goodwill)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

0

-

-

-

-

-

-

Impairment of intangible assets

-

-

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of goodwill

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Site consolidation non-cash portion

-

-

0

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on investment

-

-

0

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net equity investment gain (loss)

0

-

-13,986

-13,312

0

-

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non Cash Royalty Revenue Related To Sale Of Future Royalties

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net accretion and amortization of investments in marketable securities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable

418

-227

1,681

-60

-65

1,029

-453

135

-7,159

129

596

731

7,538

-735

-1,818

-5,804

-4,182

-628

434

6,333

3,364

1,887

-1,807

-3,446

103

-889

0

0

0

Accrued revenue

-

-

0

0

-

-

0

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred lease incentives

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Accrued revenue

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-349

397

194

1,278

360

-897

-1,145

-2,906

-2,008

0

0

0

Deferred expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-226

-231

0

0

0

Investment tax credits receivable

-

-

-

-

-

-

-

-

34

47

-134

-134

62

47

-98

-98

0

-

0

0

-

-

-

-

-

-

-

0

-

Prepaid expenses and other assets

1,110

-1,606

-75

896

-942

648

-375

-349

-118

833

43

-458

106

115

274

389

335

-159

944

1,796

1,034

773

-114

-490

-200

776

0

0

0

Other assets

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-3,127

-2,410

-553

3

36

-1,266

2,073

-826

458

736

-1,522

-604

-2,767

26

-1,515

1,780

-5,613

-2,489

853

802

7,210

6,253

1,977

155

374

130

0

0

0

Deferred revenue

-

-

-649

-974

-

-2,742

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent and inducements

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

0

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

6,483

-1,066

-16,210

-12,503

-11,956

-13,090

3,287

-530

-409

13,171

11,196

11,268

11,275

-153

0

0

0

Site consolidation accrual

-

-

-356

-538

-

1,331

770

1,090

1,029

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-709

-665

-541

-95

-87

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-69,879

-71,006

-74,728

-64,462

-64,479

-67,866

-61,140

-63,616

-51,072

-48,640

-53,116

-52,148

-63,874

-57,885

-62,403

-50,218

-50,085

-56,382

-43,887

-48,080

-39,419

-12,421

-3,008

918

5,258

-6,737

0

0

0

INVESTING ACTIVITIES
Purchase of investments

0

-

-72,404

-72,404

0

-

74,524

68,681

66,950

-35,086

-50,098

-43,543

42,627

82,551

99,087

115,519

41,024

-9,645

-9,984

15,864

0

-

0

0

-

-

-

-

-

Disposition of investments

0

-

0

0

0

-

0

0

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash acquired through acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

324

324

324

0

-

0

0

-

-

-

-

-

Proceeds from sale of property and equipment

2

11

9

34

34

25

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition of property and equipment

558

589

754

736

921

1,138

1,092

1,393

4,089

7,264

9,680

9,310

7,143

3,996

2,572

2,993

2,422

2,287

1,436

999

862

1,056

927

985

859

725

0

0

0

Net cash provided by / (used in) investing activities

-35,096

28,338

119,341

127,564

132,572

-4,127

-35,593

-54,666

-71,036

27,825

27,842

21,657

-62,346

-99,123

-101,659

-118,512

-43,446

7,682

10,544

27,834

-5,077

-42,958

-44,210

-43,977

-859

-725

0

0

0

Issuance of common shares pursuant to the Open Market Sale agreement

28,668

18,601

-61,540

-61,540

-64,017

0

0

0

0

-

-

-

-

-

-

0

-

142,177

142,177

142,177

142,175

56,477

0

0

0

-

-

-

-

Proceeds from the sale of future royalties

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Promissory note repayment

-

-

0

0

-

12,001

12,001

12,001

12,001

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of Preferred Shares, net of issuance costs

-

-

0

0

-

-

0

0

-

48,869

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common shares pursuant to exercise of options

185

307

399

834

1,567

1,382

1,307

933

202

100

66

81

78

192

168

208

1,146

1,651

1,951

2,103

1,312

2,616

2,618

2,357

2,231

389

0

0

0

Issuance of common shares pursuant to exercise of warrants

-

-

-

-

-

-

-

-

-

353

353

353

798

445

443

443

17

42

237

653

720

1,583

1,508

1,153

1,121

289

0

0

0

Net cash provided by financing activities

47,402

37,457

23,673

5,559

3,815

55,646

104,440

104,066

103,335

49,322

12,420

12,435

12,877

12,638

611

651

1,165

143,870

144,365

144,933

144,207

60,676

92,641

92,025

91,867

32,716

0

0

0

Effect of foreign exchange rate changes on cash and cash equivalents

0

-

0

0

0

-

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase / (decrease) in cash and cash equivalents

0

-

0

0

0

-

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of foreign exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-702

-1,578

1,004

8,992

3,844

4,862

-578

-8,110

-2,749

-1,792

-1,827

-3,081

-3,924

-5,031

-3,561

0

0

0

Decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-18,758

-114,921

-143,366

-154,459

-164,235

-87,504

94,592

102,912

121,938

97,919

3,470

42,342

45,042

91,235

21,693

0

0

0

Supplemental cash flow information
Fair value of warrants exercised on a cashless basis

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

1,404

0

0

0

Non-cash transactions:
Acquired property and equipment in trade payables

-

-

-

-

-

-

-

-

-

-

2,290

2,556

2,484

1,057

266

0

0

-

0

-

-

-

-

-

-

-

-

-

-

Preferred shares dividends accrued

11,412

11,149

10,916

10,691

10,470

10,091

0

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Initial investment in Genevant

-

-

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrants exercised on a cashless basis

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

1,404

0

0

0

Fair value of warrants exercised on a cashless basis

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Investment tax credits received

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

0

0

-

-

0

0

-

-

-

0

-

Acquisition of Arbutus Inc. net of cash acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

381,618

381,618

381,618

0

-

0

0

-

-

-

-

-